Bullseye Biodevices Inc. Awarded NSF STTR Phase I Grant to Advance Tumor Mapping Technology

[Hoboken, New Jersey]. Bullseye Biodevices Inc. is proud to announce it has been awarded a $305,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (NSF). This prestigious award, part of "America’s Seed Fund," will support the development of a groundbreaking electromechanical probe designed to provide surgeons with real-time, three-dimensional maps of tumor margins during robotic surgical interventions.

Current surgical methods often face challenges in precisely identifying the boundaries of a tumor, which can lead to incomplete removal and a higher risk of cancer recurrence. Bullseye Biodevices is addressing this critical gap by developing a novel contact-based biosensing technology. By measuring biophysical properties—such as bioimpedance and force assessment—the device aims to generate a "volumetric" map of the tumor. This allows for greater accuracy in tumor resection, significantly minimizing damage to healthy surrounding tissue and ultimately improving long-term patient outcomes.

The Bullseye team extends its sincere gratitude to Dr. Jennifer Kang-Mieler, PhD, for her commitment to serving as Co-PI and for her invaluable support of the project. Furthermore, Bullseye Biodevices recognizes Stevens Institute of Technology for its essential role as the subaward research institution.

September 2025